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Abstract
Introduction: It is debated whether mammographic density gives rise to more aggressive cancers. We therefore
aimed to study the influence of mammographic density on prognosis.
Methods: This is a case-only study within a population-based case-control study. Cases were all postmenopausal
women in Sweden with incident breast cancer, diagnosed 1993-1995, and aged 50-74 years. Women with pre-
diagnostic/diagnostic mammograms were included (n = 1774). Mammographic density of the unaffected breast
was assessed using a computer-assisted thresholding technique. The Cox proportional hazards model was used to
study recurrence and survival with and without stratification on surgical procedure (breast-conserving surgery vs.
mastectomy).
Results: Percentage density (PD) was associated with both local and locoregional recurrence even after adjustment
for established prognosticators; hazards ratio (HR) 1.92, p = 0.039, for local recurrence and HR 1.67, p = 0.033, for
locoregional recurrence for women with PD≥25% compared to PD<25%. Stratification on surgical procedure
showed that the associations were also present in mastectomized women. PD was neither associated with distant
recurrence nor survival.
Conclusions: High mammographic density is an independent risk factor of local and locoregional recurrence but is
neither associated with distant metastasis nor survival. The relationships with local and locoregional recurrences
were also present in women treated with mastectomy, indicating that they are not merely explained by density
masking residual disease in women treated with breast-conserving surgery. Rather there appears to be a true
association. Thus, mammographic density should possibly influence adjuvant therapy decisions in the future.
Introduction
Mammographic density (MD) is one of the strongest
risk factors for breast cancer. Women with highest den-
sity (>75%) have a fivefold increased risk compared with
women with almost entirely fatty breasts (<5%) [1]. MD
refers to the tissue composition of the breast; the
epithelium and fibrous tissue are radiodense and appear
white on a mammogram, whereas the fatty tissue is
radiolucent and appears black. MD is often given as a
percentage (percentage density, or PD), which is calcu-
lated by dividing the dense area by the total breast area.
Consequently, larger amounts of fibroglandular tissue in
relation to fatty tissue will lead to higher PD and vice
versa.
Whether MD influences prognosis is not known. There
are several possible mechanisms by which density could
affect prognosis. MD has consistently been shown to be
associated with the stromal composition of the breast [2],
which is involved in tumor progression [3]. Hence, breast
cancer originating in dense breasts may be associated with
a more aggressive disease. Furthermore, MD decreases
mammographic sensitivity since extensive density can hide
tumors (a phenomenon referred to as masking). MD may
thereby be associated with a poorer prognosis because of
later detection. Masking may also influence the risk of
recurrence, by hiding disease in the residual breast tissue
of women who undergo breast-conserving surgery, thereby
increasing the risk of recurrence. Lastly, MD may be asso-
ciated with tumor characteristics or tumor subtype.
Results are highly inconsistent, although most of these
studies show no association [4-9]. Previous studies directly
addressing the relationship between PD and survival show
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conflicting results [10-13], but the most recent and largest
study [10] failed to detect an association between pre-
diagnostic MD and survival. Hence, with this study, we
wished to investigate whether MD influences prognosis,
by studying its association with recurrence and survival.
Materials and methods
Study population
This study is an extension of a large case-control study
among all Swedish residents who were born in Sweden
and who were 50 to 74 years old at the time of enroll-
ment (1 October 1993 to 31 March 1995). Details on
data collection and subjects have been provided pre-
viously [14]. Women with incident primary invasive
breast cancer were identified via the six Swedish Regio-
nal Cancer Registries (n = 3,979), and 84% (n = 3,345)
participated. However, 19 cases were diagnosed outside
of the study period, one case had a diagnosis other than
breast cancer, and 58 cases had non-invasive breast can-
cer, rendering them ineligible and leaving 3,267 women
in the study.
For this study, the inclusion criteria were further
refined to include only post-menopausal women who
had no prior diagnosis of cancer other than non-mela-
noma skin cancer (see Eriksson et al. [6] for details).
The study base thus consisted of 2,720 breast cancer
cases.
Details on mammography retrieval have been provided
elsewhere [6]. For the eligible participants in this study, we
managed to collect mammograms for 2,046 women (75%).
However, 107 women who had only post-diagnostic mam-
mograms were excluded, as were 65 women lacking mam-
mograms of the breast contralateral to the tumor and
79 women lacking post-menopausal mammograms. The
latter exclusion is due to the fact that MD may differ his-
tologically in pre- and post-menopausal women [15] and
also may be affected differentially by hormones [16].
Lastly, images of poor quality were omitted, excluding
21 women. The median difference from date of mammo-
graphy to study entrance was 50 days.
Values of descriptive statistics (means and proportions)
for women excluded because of the factors above did not
differ significantly from those for included women (n =
1,774) for body mass index (BMI), breast cancer heredity,
previous benign breast disease, age at menarche, oral con-
traceptive use, age at first birth, parity, breast feeding, age
at menopause, and hormone replacement therapy (HRT)
use. However, there was a difference in age at study
entrance (62.9 years for included women and 63.6 years
for excluded women; P = 0.015).
Approval for the study was given by the ethical review
boards in the respective regions in which the subjects
were based: the Regional Ethical Review Board in Gothen-
burg, the Regional Ethical Review Board in Linköping, the
Regional Ethical Review Board in Malmö-Lund, the Regio-
nal Ethical Review Board in Stockholm (at Karolinska
Institutet), the Regional Ethical Review Board in Umeå,
and the Regional Ethical Review Board in Uppsala. Prior
to participation via a mailed questionnaire, written consent
was obtained from all patients.
Data collection and classification
Data on sociodemographic, anthropometric, hormonal,
and lifestyle factors were collected by means of a postal
questionnaire. Because date of mammography was prior
to study entrance, the variables of age, menopausal sta-
tus, and HRT use were reassessed according to date of
mammography. This was not possible for BMI as we had
information on BMI at study entrance and 1 year prior to
study entrance only. However, it has previously been
shown that inter-individual variations in BMI are small
[17], and the difference in BMI at study entrance and
1 year prior to this was 0.05 units (standard deviation of
1.2) for our study participants.
HRT use was classified as ‘current’, ‘former’, or ‘never’
to indicate how recent it was. Because the influence of
HRT on MD is supposed to diminish within 3 weeks of
cessation [18], former users were those who discontin-
ued use of HRT more than 1 month prior to date of
mammography. All compounds, modes of administra-
tion, and potencies - except for low-potency, estrogen-
only pharmaceuticals, since these have not been shown
to increase breast cancer risk - were included in the
HRT variable [14].
We used the national registration numbers to retrieve
patient records and register information. Between 2000
and 2002, we collected information on primary surgery,
adjuvant treatment (endocrine therapy, chemotherapy,
and radiotherapy), tumor characteristics, possible recur-
rence, and reason for diagnostic mammography from
surgical and oncological patient records throughout
Sweden.
We collected information on emigrations from the
Swedish National Population Register and on the date and
cause of death until 31 December 2008 from the Swedish
Causes of Death Registry. The latter registry covers all
residents in Sweden with essentially no missing deaths and
has been shown to correctly classify 98% of breast cancer
deaths [19]. The follow-up of vital status is thus virtually
complete.
Grade was classified according to the Nottingham his-
tologic grade or the Bloom-Richardson scale into three
groups. Tumors were considered estrogen receptor
(ER)-positive or progesterone receptor (PR)-positive if
they contained at least 0.05 fmol receptor/μg DNA or at
least 10 fmol receptor/mg protein.
Type of surgery was classified as breast-conserving
surgery or mastectomy independent of axillary surgery
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because 98% of our study participants had axillary
lymph node clearance carried out. Local recurrence
included recurrence in the residual ipsilateral breast,
scar tissue, or chest wall. Locoregional recurrence
included both local recurrences and recurrences in
regional lymph nodes. During the collection of follow-
up information from clinical records, the study subjects’
follow-up period was marked as complete or incomplete
depending on whether follow-up information was com-
plete or missing until date of retrieval. The follow-up
time for recurrence variables was thus computed as fol-
lows: If the specific recurrence occurred, the follow-up
time was computed from the date of diagnosis to the
date of that specific recurrence; if the specific recurrence
did not occur and follow-up information from medical
records was considered complete, the follow-up time
was computed from the date of diagnosis to the date of
medical record retrieval or the date of death, whichever
came first; if information on follow-up was considered
incomplete, the follow-up time was computed from the
date of diagnosis to the last documented date in the
medical record or the date of death, whichever came
first.
Mammographic density data
Film mammograms of the medio-lateral oblique view were
digitized by using an Array 2905HD Laser Film Digitizer
(Array Corporation, Tokyo, Japan), which covers a range
of 0 to 4.7 optical density. The medio-lateral oblique view
was used since this was the routine view used at mammo-
graphy screening in Sweden. The density resolution was
set at 12-bit spatial resolution. We used Cumulus, a com-
puter-assisted thresholding technique, to assess density
[20] of the mammogram contralateral to the tumor. For
each image, a trained observer (LE) set the appropriate
gray-scale threshold levels that defined the edge of the
breast and that distinguished dense from non-dense tissue.
The software calculated the total number of pixels within
the entire region of interest and within the region identi-
fied as dense. The PD was then calculated from these
values (dense area divided by total breast area). The
images were measured together with approximately
the same number of images for healthy women, and the
reader was blinded to case-control status and, naturally, to
prognosis. A random 10% of the images were included as
replicates to assess the intra-observer reliability, which was
high (R2 of 0.92).
Statistical analysis
As in the report by Eriksson and colleagues [6], density
was used as a binary variable throughout because it is
more clinically relevant than a continuous measure and
more easily interpreted. The cutoff was set at 25% defin-
ing the highest quartile in our cohort, i.e. 25% of the
study population had a PD of at least 25%. We included
post-menopausal women only. The MD in these women
is lower and more homogeneous than in a combined
pre- and post-menopausal population. We did not cate-
gorize PD according to the commonly used categories
introduced by Boyd and colleagues [21], since the num-
bers of women in the highest categories were relatively
few. Both recurrences and deaths are relatively rare
events, and we wanted a fairly large number of women
in each density category in order to avoid committing a
type II error due to low power.
The descriptive characteristics of cases with high den-
sity versus cases with lower density were compared by
using chi-squared tests for categorical variables and Stu-
dent t tests for continuous variables. We also carried
out age-adjusted analyses pertaining to the above by
using logistic regression.
The survival analyses were carried out by using the Cox
proportional hazards model. We made use of two mod-
els. The first model was carried out to attempt to study
the association between MD and recurrence and survival
variables. We therefore included only age (continuous),
BMI (continuous), and HRT use (categorical) in this
model since these variables are strongly associated with
MD and breast cancer risk [22] and may influence prog-
nosis [23-26]. The second model was carried out to show
whether any possible associations were independent of
established prognosticators. Therefore, in addition to
including the variables in the first model, the second
model included the following variables: tumor size (con-
tinuous), lymph node metastasis (continuous), ER status
(categorical), PR status (categorical), grade (categorical),
and mode of detection (binary: screening-detected versus
non-screening-detected cancer) [27,28]. Whereas less
than 5% of our study population were missing informa-
tion on mode of detection, tumor size, and presence of
lymph node metastasis, respectively, approximately 30%
were missing information on grade and ER and PR status.
We thus added a missing category to these variables. All
analyses were carried out by using the statistical software,
STATA 12.1 (StataCorp LP, College Station, TX, USA).
Results
The mean PD was 18%. Age at mammography (P < 0.0001),
BMI (P <0.0001), previous oral contraceptive use (P <
0.001), parity and age at first birth (P = 0.005), HRT use
(P < 0.001), and previous benign breast disease (P < 0.001)
were all associated with PD (Table 1). After adjustment for
age, PD was still statistically significantly associated with
BMI (P < 0.001), parity and age at first birth (P = 0.001),
HRT use (P < 0.001), and previous benign breast disease
(P < 0.001) as well as age at menopause (P = 0.046).
There were statistically significant differences between
women with a PD of at least 25% compared with women
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with a PD of less than 25% for mode of detection (P =
0.011) and tumor size (P = 0.007) as well as a tendency
for women with dense breasts to develop locoregional
recurrence more often (P = 0.056) (Table 2).
Results from survival analyses are reported in Table 3.
PD was associated with local and locoregional recurrence
both before (hazard ratio (HR) for local recurrence 1.99,
95% confidence interval (CI) 1.09 to 3.66; HR for locore-
gional recurrence 1.84, 95% CI 1.16 to 2.91) and after
adjustment for established prognosticators (HR for local
recurrence 1.92, 95% CI 1.03 to 3.57; HR for locoregional
recurrence 1.67, 95% CI 1.04 to 2.69). No associations
between PD, distant metastasis, breast cancer-specific sur-
vival, and overall survival were observed. After finding
associations between PD and local and locoregional recur-
rence, we investigated whether there was a dose-response
relationship by categorizing PD into quartiles. We found
support of such a relationship (Table 4).
The associations described in Tables 3 and 4 between
PD and local and locoregional recurrence could be due
to the masking of residual disease by MD in women who
underwent breast-conserving surgery. We therefore redid
the analyses pertaining to PD, local, and locoregional
recurrence, stratifying on surgical procedure (Table 5).
For women who underwent mastectomy, the HRs for
local and locoregional recurrence were 2.93 (95% CI 1.03
to 8.39) and 2.16 (95% CI 1.02 to 4.54), respectively, after
full adjustment. For women who underwent breast-
conserving surgery, the HRs for local and locoregional
recurrence were 1.48 (95% CI 0.67 to 3.25) and 1.57 (95%
CI 0.83 to 2.97), respectively, after full adjustment.
Although we used PD as a binary variable, we also car-
ried out analyses by using PD as a continuous measure.
This did not change the interpretation of the results; for
example, P = 0.008 for the association between continu-
ous PD and locoregional recurrence before adjustment
Table 1 Descriptive statistics based on percentage density
All cases (n = 1,774)
Unadjusted Age-adjusted
PD <25% (n = 1,329) PD ≥25% (n = 445) P value P value
Age at mammography, years 63.1 59.0 <0.001
Body mass index 26.4 23.9 <0.001 <0.001
Age at menarche, years 13.6 13.5 0.719 0.310
Oral contraceptive use <0.001 0.484
Yes 410 (31%) 184 (41%)
No 914 (69%) 261 (59%)
Parity and age at first birth 0.005 0.001
Nulliparous 173 (13%) 79 (18%)
Parity ≤2 and age at first birth ≤25 386 (29%) 136 (31%)
Parity ≤2 and age at first birth >25 403 (30%) 144 (32%)
Parity >2 and age at first birth ≤25 272 (20%) 63 (14%)
Parity >2 and age at first birth >25 96 (7%) 23 (5%)
Breast feeding 0.174 0.069
Yes 940 (80%) 316 (77%)
No 229 (20%) 93 (23%)
Age at menopause, years 50.4 50.5 0.506 0.046
HRT use <0.001 <0.001
Never 974 (74%) 244 (56%)
Past 70 (5%) 70 (16%)
Current 268 (20%) 124 (28%)
Previous benign breast disease <0.001 <0.001
Yes 161 (12%) 89 (20%)
No 1,163 (88%) 354 (80%)
Breast cancer heredity 0.633 0.829
Yes 200 (15%) 64 (15%)
No 1,091 (85%) 376 (85%)
Values other than P values are presented as number (percentage) or mean. HRT, hormone replacement therapy; PD, percentage density.
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Table 2 Description of mode of detection, tumor characteristics, treatment, and prognosis variables based on
percentage density
All cases (n = 1,774) PD <25% (n = 1,329) PD ≥25% (n = 445) P value
Mode of detection 0.011
Screening-detected 1,115 (64%) 867 (67%) 248 (57%)
Referral for check-up, no symptoms 25 (1%) 18 (1%) 7 (2%)
Referral due to HRT use, no symptoms 21 (1%) 15 (1%) 6 (1%)
Symptomatic 551 (32%) 384 (30%) 167 (39%)
Referral, other reason 18 (1%) 13 (1%) 5 (1%)
Tumor size, mm 16.8 16.4 18.0 0.007
Lymph node metastasis 0.581
Positive 480 (28%) 362 (29%) 118 (27%)
Negative 1,221 (72%) 905 (71%) 316 (73%)
Histopathologic classification 0.230
Ductal 1,268 (73%) 957 (73%) 311 (72%)
Lobular 199 (11%) 140 (11%) 59 (14%)
Other 268 (15%) 206 (16%) 62 (14%)
ER status 0.733
ER-positive 971 (79%) 727 (79%) 244 (78%)
ER-negative 256 (21%) 189 (21%) 67 (22%)
PR status 0.779
PR-positive 808 (67%) 602 (67%) 206 (68%)
PR-negative 396 (33%) 298 (33%) 98 (32%)
Grade 0.382
1 197 (17%) 151 (17%) 46 (15%)
2 510 (43%) 382 (44%) 128 (42%)
3 475 (41%) 342 (39%) 133 (43%)
Chemo- and endocrine therapy 0.507
Chemotherapy only 51 (3%) 34 (3%) 17 (4%)
Endocrine therapy only 788 (46%) 590 (45%) 198 (46%)
Both 81 (5%) 59 (5%) 22 (5%)
None 812 (47%) 615 (47%) 197 (45%)
Locoregional radiotherapy 0.425
Yes 1,098 (63%) 816 (63%) 282 (65%)
No 633 (37%) 481 (37%) 152 (35%)
Type of breast operation 0.580
Breast-conserving surgery 1,046 (61%) 786 (61%) 260 (60%)
Mastectomy 683 (40%) 509 (39%) 174 (40%)
No surgery 3 (0%) 3 (0%) 0 (0%)
Local recurrence 0.304
Yes 62 (4%) 43 (3%) 19 (4%)
No 1,668 (96%) 1,253 (97%) 415 (96%)
Locoregional recurrence 0.056
Yes 103 (6%) 69 (5%) 34 (8%)
No 1,627 (94%) 1,227 (95%) 400 (92%)
Distant metastasis 0.361
Yes 187 (11%) 135 (10%) 52 (12%)
No 1,544 (89%) 1,162 (90%) 382 (88%)
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for established prognosticators and P = 0.032 after full
adjustment.
Discussion
MD is one of the strongest risk factors for breast cancer,
and we have shown that it also increases risk of local
and locoregional recurrence after diagnosis of invasive
breast cancer. We found no association between density
and distant metastasis or between density and survival
in our post-menopausal study population.
There was support of a dose-response relationship
between PD and both local and locoregional recurrence.
Women in the highest PD quartile (PD ≥25.07) had a
threefold higher risk of local recurrence and twofold
higher risk of locoregional recurrence compared with
women in the lowest PD quartile (PD <6.47; Table 4),
independent of established breast cancer prognosticators.
The association between PD and locoregional recurrence
is in agreement with the two previously published studies
investigating this relationship in women with invasive
Table 2 Description of mode of detection, tumor characteristics, treatment, and prognosis variables based on percen-
tage density (Continued)
Breast cancer death within 5 years 0.405
Yes 124 (7%) 89 (7%) 35 (8%)
No 1,649 (93%) 1,239 (93%) 410 (92%)
Breast cancer death within 10 years 0.204
Yes 213 (12%) 152 (11%) 61 (14%)
No 1,560 (88%) 1,176 (89%) 384 (86%)
Death within 5 years independent of cause 0.902
Yes 174 (10%) 131 (10%) 43 (10%)
No 1,599 (90%) 1,197 (90%) 402 (90%)
Death within 10 years independent of cause 0.599
Yes 358 (20%) 272 (20%) 86 (19%)
No 1,415 (80%) 1,056 (80%) 359 (81%)
Values are presented as number (percentage) or mean. ER, estrogen receptor; HRT, hormone replacement therapy; PD, percentage density; PR, progesterone
receptor.
Table 3 Association of percentage density with breast cancer recurrence and survival
Model 1a Model 2b
HRc 95% CI P value HRc 95% CI P value
Local recurrence
62 events
Total time at risk = 9,683 years
1.99 1.09-3.66 0.026 1.92 1.03-3.57 0.039
Locoregional recurrence
103 events
Total time at risk = 9,606 years
1.84 1.16-2.91 0.010 1.67 1.04-2.69 0.033
Distant recurrence
181 events
Total time at risk = 9,618 years
1.28 0.90-1.82 0.170 1.08 0.74-1.56 0.698
5-year breast cancer-specific survival
124 events
Total time at risk = 8,489 years
1.25 0.82-1.92 0.299 0.97 0.61-1.54 0.908
10-year breast cancer-specific survival
213 events
Total time at risk = 16,016 years
1.34 0.97-1.85 0.080 1.08 0.77-1.53 0.644
Overall 5-year survival
174 events
Total time at risk = 8,489 years
1.07 0.73-1.55 0.742 0.89 0.60-1.32 0.554
Overall 10-year survival
358 events
Total time at risk = 16,016 years
1.14 0.87-1.48 0.343 0.99 0.75-1.29 0.921
aAdjusted for age, body mass index (BMI), and hormone replacement therapy (HRT) use;
badjusted for age, BMI, HRT use, mode of detection, tumor size, lymph node metastasis, estrogen receptor status, progesterone receptor status, and grade;
chazard ratio (HR) comparing percentage density (PD) ≥25% to PD <25%. CI, confidence interval.
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breast cancer [13,29], although they both [13,29] were
limited to women who had undergone breast-conserving
surgery. Even though most locoregional recurrences
occur in women who have undergone breast-conserving
surgery, there remains a risk of developing recurrence in
the scar tissue, chest wall, and regional lymph nodes after
mastectomy. Furthermore, if an association between MD
and locoregional recurrence is restricted to women who
underwent breast-conserving surgery, then it could sim-
ply be because density masked residual disease in the
conserved breast. This reservation is especially important
in our study since we lacked information on the status of
the surgical margin. We thus stratified on type of breast
surgery and found that the relationship also was present
in the group of women who underwent mastectomy,
undermining this hypothesis. We do not wish to draw
any conclusions on whether type of surgery influences
the risk of recurrence, since differences in personal and
clinical characteristics (for example, age, tumor size, and
comorbidity) will be different in the groups selected for
the two different surgical techniques. This will lead to
confounding by indication.
We did not see an association between density and
distant recurrence or with survival. Distant metastasis is
closely linked with breast cancer mortality, whereas
locoregional recurrence has a moderate impact on survi-
val [30]. Since we had only a 10-year follow-up of survi-
val, we cannot exclude the possibility that there is a
relationship between PD and long-term survival or that
there is a small effect of PD on survival, requiring even
Table 4 Association between mammographic density categorized into quartiles and local and locoregional recurrence
Local recurrence Locoregional recurrence
HR 95% CI P value HR 95% CI P value
Model 1a 0.008 0.012
PD, 1st quartileb 1.00 (Ref.) 1.00 (Ref.)
PD, 2nd quartilec 1.72 0.78-3.78 1.43 0.79-2.60
PD, 3rd quartiled 1.91 0.86-4.24 1.34 0.72-2.50
PD, 4th quartilee 3.14 1.38-7.16 2.36 1.27-4.39
Model 2f 0.017 0.035
PD, 1st quartileb 1.00 (Ref.) 1.00 (Ref.)
PD, 2nd quartilec 1.80 0.80-4.05 1.38 0.75-2.53
PD, 3rd quartiled 1.78 0.77-4.11 1.29 0.68-2.45
PD, 4th quartilee 3.03 1.28-7.17 2.10 1.11-3.97
aAdjusted for age, body mass index (BMI), and hormone replacement therapy (HRT) use;
bpercentage density (PD) <6.46, n = 443;
c6.46 ≤ PD <13.66, n = 444;
dPD 13.66 ≤ PD <25.07, n = 444;
ePD ≥25.07, n = 443;
fadjusted for age, BMI, HRT use, mode of detection, tumor size, lymph node metastasis, estrogen receptor status, progesterone receptor status, and grade. CI,
confidence interval; HR, hazard ratio; Ref., reference value.
Table 5 Association between percentage density (≥25% compared with <25%) and local recurrence stratified on
surgical method
Breast-conserving surgery Mastectomy
Local recurrence 41 events
Time at risk = 5,959 years
21 events
Time at risk = 3,734 years
HR CI P value HR CI P value
Model 1a 1.53 0.70-3.31 0.286 3.44 1.26-9.38 0.016
Model 2b 1.48 0.67-3.25 0.334 2.93 1.03-8.39 0.045
Locoregional recurrence 61 events
Time at risk = 5,924 years
42 events
Time at risk = 3,690 years
HR CI P value HR CI P value
Model 1a 1.45 0.78-2.70 0.242 2.69 1.34-5.43 0.006
Model 2b 1.57 0.83-2.97 0.166 2.16 1.02-4.54 0.044
aAdjusted for age, body mass index (BMI), and hormone replacement therapy (HRT) use.
bAdjusted for age, BMI, HRT use, mode of detection, tumor size, lymph node metastasis, estrogen receptor status, progesterone receptor status, and grade. CI,
confidence interval; HR, hazard ratio.
Eriksson et al. Breast Cancer Research 2013, 15:R56
http://breast-cancer-research.com/content/15/4/R56
Page 7 of 9
larger studies to identify the association. However, the
lack of an association between MD, distant metastasis,
and survival is in accordance with both previous studies
pertaining to MD and distant metastasis [13,29] and two
of three studies on MD and survival [10,11,13]. The
conflicting study relating to density and prognosis [12]
showed a lower case fatality for women with high den-
sity compared with women with low density. However,
because only age was adjusted for, this relationship is
most likely due to confounding.
The mean density was relatively low in this study popu-
lation since all women were post-menopausal when the
mammograms were taken. The mean age at mammogra-
phy was thus relatively high (approximately 62 years of
age). The study population was originally population-
based. Hence, we had information on breast cancer risk
factors on 84% of all women who were 50 to 74 years of
age and whose invasive breast cancer was diagnosed in
Sweden during 1 October 1993 to 31 March 1995, and we
were able to compare this information with the women
who were not included in the present study. We found
that there were no differences in risk factors (for example,
BMI, family history, parity, breast feeding, and HRT use)
except for a difference in age at study entrance of the ori-
ginal study (62.9 years for included women compared with
63.6 years for excluded women; P = 0.015). Thus, our den-
sity measurements should be representative for a post-
menopausal cohort. Because the reader was blinded to
outcomes, any measurement error would be a non-differ-
ential misclassification of exposure and thus would only
attenuate results. However, the reader who was trained by
Norman Boyd, an expert on MD and one of the develo-
pers of Cumulus [20], regularly calibrated herself against
his measurements and had a high intra-observer correla-
tion (R2 = 0.92), which should minimize exposure
misclassification.
Our study has several strengths: the population-based
design, size, and detailed covariate information, includ-
ing mode of detection, quantitative semi-automated
density measurements to minimize exposure misclassifi-
cation, and long and virtually complete follow-up of
vital status and cause of death. A limitation of our study
was that the study population was restricted to post-
menopausal women; hence, our results may not be
applicable to pre-menopausal populations. We also
lacked information on HER2 status and Ki67 since they
were not clinically in use in Sweden at the time breast
cancer was diagnosed in our participants. Both HER2-
status and Ki67 influence prognosis [31,32]. However,
for these factors to have influenced our results, they
must be associated with MD, and at present there is no
evidence of such an association [7,9,33,34].
How could MD influence risk of local and locoregio-
nal recurrence but not distant metastasis? We can only
speculate on the mechanisms behind this. MD could
increase the risk of self-seeding, a process in which dis-
seminated tumor cells return and colonize the primary
tumor site [35]. In contrast to metastasis, which requires
the ability to enter, survive, and colonize a new site, self-
seeding demands little or no adaptation since the circu-
lating tumor cell returns to a familiar environment [36].
Since disseminated tumor cells can reside in a dormant
manner in new organs without giving rise to metastatic
colonies, seeding of the primary site does not require
manifest metastasis [36]. This has been presented as an
explanation for why local recurrence can follow a com-
plete eradication of the primary tumor [35].
MD has been hypothesized to give rise to more aggres-
sive tumors due to the increased stromal composition of
the breast and increased deposition of collagen [15,37-39].
Despite this, we and others [13,29] were not able to show
an association between MD and risk of distant metastasis.
Perhaps, however, density does increase risk of dissemina-
tion, but the organ of preference is the primary tumor site.
Conclusions
High MD increases the risk of local and locoregional
recurrence but not distant recurrence or survival. The
relationships with local and locoregional recurrences
were even present in women who underwent mastectomy
and therefore are not due merely to the masking of resi-
dual disease by MD in women who underwent breast-
conserving surgery. Instead, there appears to be a true
association. MD seems to be an independent risk factor
of local and locoregional recurrence and should possibly
influence adjuvant therapy decisions in the future.
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